CDKN2A common variants and their association with melanoma risk: a population-based study.

The population frequencies of the CDKN2A variants remain undetermined. In Poland there are three common variants of CDKN2A: an alanine to threonine substitution (A148T), Nt500c>g and Nt540c>t, which have been detected in other populations. To establish if they are associated with an increased malignant melanoma (MM) risk we did an association study based on genotyping 471 patients with MM and 1,210 random control subjects from the same Polish population. We found a significantly increased frequency of the A148T variant among patients with MM (7.0%) in comparison with the general population (2.9%). The incidence of the A148T variant remained greater in both unselected and familial melanoma subgroups. A statistically significant positive association was seen for unselected MM (odds ratio, 2.529; P = 0.0003), especially in patients diagnosed under 50 years of age (odds ratio, 3.4; P = 0.0002). The A148T carrier population (heterozygous G/A alleles) was more likely to have a relative with malignancy compared with the noncarrier population (57% versus 36%, respectively; P = 0.03). Further examination of the CDKN2A promoter sequence done in 20 melanoma patients with the A148T change (heterozygous G/A alleles) and 20 patients with MM without this alteration identified it was in linkage disequilibrium with a polymorphism in the promoter region at position P-493. We found no statistically significant overrepresentation of the Nt500c>g and the Nt540c>t polymorphisms in the Polish melanoma population. In conclusion, the A148T variant of the CDKN2A gene seems to be associated with an increased risk of development of MM. Additional studies are required to confirm whether this particular change is associated with increased risk of other nonmelanoma malignancies.

[1]  R. Go,et al.  Ancestry reported by white adults with cutaneous melanoma and control subjects in central Alabama , 2004, BMC Cancer.

[2]  A. Jakubowska,et al.  A high proportion of founder BRCA1 mutations in Polish breast cancer families , 2004, International journal of cancer.

[3]  R. Scott,et al.  Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer , 2004, International journal of cancer.

[4]  J. Lubiński,et al.  A novel founder CHEK2 mutation is associated with increased prostate cancer risk. , 2004, Cancer research.

[5]  A. Baccarelli,et al.  XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk , 2004, British Journal of Cancer.

[6]  J. Barrett,et al.  An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. , 2002, The Journal of investigative dermatology.

[7]  K. Hemminki,et al.  Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. , 2002, The American journal of pathology.

[8]  A. Goldstein,et al.  High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. , 2002, American journal of medical genetics.

[9]  K. Hemminki,et al.  A single nucleotide polymorphism in the 3′untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare , 2001, International journal of cancer.

[10]  P. Pollock,et al.  Mutation analysis of the CDKN2A promoter in Australian melanoma families , 2001, Nature Genetics.

[11]  D. Tomescu,et al.  Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. , 2001, Carcinogenesis.

[12]  J. Hansson,et al.  CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. , 2000, Cancer research.

[13]  D. Bishop,et al.  Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.

[14]  M. Greene.  The genetics of hereditary melanoma and nevi , 1999, Cancer.

[15]  D. Duffy,et al.  CDKN2A variants in a population-based sample of Queensland families with melanoma. , 1999, Journal of the National Cancer Institute.

[16]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[17]  D. Bishop,et al.  Germline mutations of the CDKN2 gene in UK melanoma families. , 1997, Human molecular genetics.

[18]  M. Inganäs,et al.  Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. , 1997, Journal of the National Cancer Institute.

[19]  K. Isselbacher,et al.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Sutherland,et al.  Cancer‐associated mis‐sense and deletion mutations impair p16INK4 CDK inhibitory activity , 1996, International journal of cancer.

[21]  Thomas Rg,et al.  Familial melanoma and pancreatic cancer. , 1996 .

[22]  N. Hayward,et al.  Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. , 1995, Human molecular genetics.

[23]  M. Tucker,et al.  Genetic epidemiology of familial melanoma. , 1995, Dermatologic clinics.

[24]  L. Sandkuijl,et al.  CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple‐mole melanoma (FAMMM) syndrome families , 1995, Melanoma research.

[25]  H. Varmus,et al.  Mutations associated with familial melanoma impair p16INK4 function , 1995, Nature Genetics.

[26]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[27]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[28]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[29]  K. Lamperska,et al.  Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. , 2002, Acta biochimica Polonica.

[30]  L. Bonetta.  Virus, cells and videotape , 2002, Nature Medicine.

[31]  D. Duffy,et al.  Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? , 2000, American journal of human genetics.

[32]  G. Bianchi‐Scarrǎ,et al.  Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. , 1996, The New England journal of medicine.

[33]  N. Gruis,et al.  Familial melanoma and pancreatic cancer. , 1996, The New England journal of medicine.